Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Mpm Capital
BioCentury | Mar 26, 2025
Finance
Early lessons from the NewCo Model
Panelists on a Capital Markets Preview webinar from BioCentury and Oppenheimer debate the hottest trend in dealmaking
BioCentury | Feb 11, 2025
Politics, Policy & Law
Conflict over NIH funding poses tough choices for biopharma
Cuts to NIH funding foreshadow bigger challenges for biomedical research, tough trade-offs for biotech and pharma companies
BioCentury | Feb 6, 2025
Guest Commentary
Call to action: Defending the NIH, the NSF and the foundation of American science — a Guest Commentary
There is an assault on the foundation of U.S. science: Silence is not an option
BioCentury | Jan 22, 2025
Finance
Biotech bulls and bears in 2025
Public Markets Preview: Will political uncertainty resolve in biotech’s favor or lead to economically damaging policy?
BioCentury | Sep 18, 2024
Finance
Biotech fundraising conditions brighten with bolder Fed rate cut
With more cuts likely, falling interest rate cycle could draw investors to sector
BioCentury | Aug 6, 2024
Finance
With an eye toward ‘inflection capital’ for biotechs, TPG focuses new fund on clinical POC
Firm has $580M in to invest in life sciences strategy
BioCentury | Feb 22, 2024
Finance
Venture report: Frontier enters clinic with $80M round; ORI’s new $260M fund
Plus: Launches for Sofinnova-backed AI company Bioptimus, peptide start-up Insamo
BioCentury | Jan 30, 2024
Emerging Company Profile
NextPoint: a new checkpoint target to extend immunotherapy’s reach
Checkpoint inhibitor against HHLA2-KIR3DL3 axis might work where PD-1 blockers don’t
BioCentury | Jan 8, 2024
Deals
Merck acquisition brings back hope for Harpoon’s trispecific technology
Merck will acquire Harpoon and its DLL3 trispecific for $680M
BioCentury | Dec 16, 2023
Data Byte
EMA’s CHMP green-lights Casgevy, Skyclarys and Velsipity
December highlights also include confirmation of non-renewal for Blenrep, plus recommendations for two therapies for neglected tropical diseases
Items per page:
1 - 10 of 695